Get regular updates to your inbox.
The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether to approve Soleno Therapeutics’ extended-release formulation of diazoxide choline — known as DCCR — for curbing excessive hunger in people with Prader-Willi syndrome (PWS). The therapy candidate is designed for use in…
Read more
Hospitalizations among people with Prader-Willi syndrome (PWS) are characterized by higher healthcare utilization and complexity compared with non-PWS patients, according to a large-scale analysis of a U.S.-based administrative claims database. In addition to high rates of obesity, PWS patients had longer hospital stays, higher associated costs, and more in-hospital…
Prader-Will syndrome is a rare and complex genetic condition that results in a variety of physical and mental symptoms. Learn more about the disease here.
Prader-Willi is caused by genetic changes in a particular area of chromosome 15. Learn more about what causes the disease here.
Symptoms of Prader-Willi range from physical impairments to cognitive and behavioral issues. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
